Posted by Surbhi on July 17 2026 at 03:54 PM
public
The minimal residual disease (MRD) testing market — molecular diagnostic assays that detect trace, sub-clinical cancer cells or circulating tumor DNA remaining after treatment, often months befor...
Posted by Surbhi on July 17 2026 at 02:47 PM
public
The targeted sequencing and resequencing market — next-generation sequencing (NGS) workflows that focus on a defined, clinically relevant set of genes or genomic regions rather than sequencing an...
Posted by Surbhi on June 29 2026 at 05:01 PM
public
KRAS inhibitor breakthroughs — the targeted therapies addressing the most frequently mutated oncogene in human cancers (present in approximately 25% of all tumors) that was considered pharmacolog...
The cancer gene therapy market represents one of the most dynamic and innovation-driven areas of modern oncology, centered on the use of genetic material to modify, repair, silence, or introduce ...
